1. Home
  2. KBDC vs IVA Comparison

KBDC vs IVA Comparison

Compare KBDC & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kayne Anderson BDC Inc.

KBDC

Kayne Anderson BDC Inc.

HOLD

Current Price

$14.32

Market Cap

980.7M

Sector

N/A

ML Signal

HOLD

Logo Inventiva S.A. American Depository Shares

IVA

Inventiva S.A. American Depository Shares

HOLD

Current Price

$4.02

Market Cap

883.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KBDC
IVA
Founded
2021
2011
Country
United States
France
Employees
N/A
77
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
980.7M
883.8M
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
KBDC
IVA
Price
$14.32
$4.02
Analyst Decision
Buy
Strong Buy
Analyst Count
5
10
Target Price
$15.50
$16.20
AVG Volume (30 Days)
201.9K
466.4K
Earning Date
05-11-2026
03-30-2026
Dividend Yield
13.16%
N/A
EPS Growth
N/A
N/A
EPS
0.43
N/A
Revenue
N/A
N/A
Revenue This Year
$193.84
N/A
Revenue Next Year
$9.00
$751.20
P/E Ratio
$33.79
N/A
Revenue Growth
N/A
N/A
52 Week Low
$13.06
$2.94
52 Week High
$16.28
$7.98

Technical Indicators

Market Signals
Indicator
KBDC
IVA
Relative Strength Index (RSI) 43.85 32.13
Support Level $14.02 $3.77
Resistance Level $14.70 $4.67
Average True Range (ATR) 0.29 0.32
MACD -0.07 -0.12
Stochastic Oscillator 20.00 12.35

Price Performance

Historical Comparison
KBDC
IVA

About KBDC Kayne Anderson BDC Inc.

Kayne Anderson BDC Inc is an externally managed, closed-end, non-diversified management investment company that has elected to be regulated as a business development company, investing mainly in first-lien senior secured loans, with a secondary focus on unitranche and split-lien loans to middle-market companies. Its investment objective is to generate current income and, to a lesser extent, capital appreciation mainly through debt investments in middle-market companies.

About IVA Inventiva S.A. American Depository Shares

Inventiva SA is a France-based clinical-stage biopharmaceutical company focused on the development of oral small-molecule therapies for the treatment of MASH. The wholly-owned research and development facility and a team with expertise and experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging the expertise, the company is also advancing lanifibranor for the treatment of MASH and has a pipeline of earlier-stage therapeutic programs in oncology. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France.

Share on Social Networks: